Lundbeck Still Assessing Future Of Antipsychotic After Phase III Failure, Says CEO
Executive Summary
Deborah Dunsire, Lundbeck’s new CEO, talks to Scrip about the fallout from its recent Phase III setback, and how she sees the road ahead for CNS clinical research.
Copenhagen-based Lundbeck Inc. recently suffered a setback in its Phase III DAYBREAK trial of Lu AF35700 for treatment-resistant schizophrenia.
The novel antipsychotic didn’t show statistical superiority versus conventional therapy on the primary endpoint (change in Total PANSS from randomization to week 10), with the announcement leaving investors worried about the Danish company's pipeline. (Also see "The Darkest Hour Is After DAYBREAK For Lundbeck’s New Antipsychotic " - Scrip, 26 Oct, 2018.)
Newly installed CEO Deborah Dunsire spoke to Scrip on the sidelines of the recent BIO-Europe conference about the company’s route forward for this much-needed treatment. She also updated Scrip on Lundbeck’s pipeline, and timelines for study readouts.